Janet K Coller

List of Publications by Citations

Source: https://exaly.com/author-pdf/6354584/janet-k-coller-publications-by-citations.pdf
Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62 papers	1,913 citations	23 h-index	42 g-index
65 ext. papers	2,275 ext. citations	4.5 avg, IF	4.67 L-index

#	Paper	IF	Citations
62	Pharmacogenetics of opioids. *Clinical Pharmacology and Therapeutics*, **2007**, 81, 429-44	6.1	262
61	Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence. *Pharmacology & Therapeutics*, **2012**, 134, 219-45	13.9	131
60	ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. *Clinical Pharmacology and Therapeutics*, **2006**, 80, 682-90	6.1	124
59	The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. *British Journal of Clinical Pharmacology*, **2002**, 54, 157-67	3.8	107
58	CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. *British Journal of Clinical Pharmacology*, **2004**, 57, 287-97	3.8	100
57	Role of active metabolites in the use of opioids. *European Journal of Clinical Pharmacology*, **2009**, 65, 121-39	2.8	83
56	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. *Cancer*, **2020**, 126, 4423-4431	6.4	82
55	Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms. *Molecular Cancer Therapeutics*, **2016**, 15, 1376-86	6.1	72
54	Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. *British Journal of Pharmacology*, **2012**, 165, 1319-29	8.6	64
53	Attenuation of microglial and IL-1 signaling protects mice from acute alcohol-induced sedation and/or motor impairment. *Brain, Behavior, and Immunity*, **2011**, 25 Suppl 1, S155-64	16.6	63
52	Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: comparison of different mouse strains. *Brain, Behavior, and Immunity*, **2011**, 25, 1223-32	16.6	47
51	Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours. *The Histochemical Journal*, **2001**, 33, 329-36		42
50	CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. *British Journal of Clinical Pharmacology*, **2015**, 80, 276-84	3.8	39
49	The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. *British Journal of Clinical Pharmacology*, **2010**, 70, 844-53	3.8	38
48	The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. *Drug Metabolism and Disposition*, **2013**, 41, 1264-72	4	35
47	OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. *Pharmacogenetics and Genomics*, **2011**, 21, 902-5	1.9	35
46	Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence. *Pharmacogenetics and Genomics*, **2009**, 19, 869-76	1.9	35

45	Pharmacogenomics of methadone maintenance treatment. *Pharmacogenomics*, **2014**, 15, 1007-27	2.6	33
44	ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. *Pharmacogenomics and Personalized Medicine*, **2012**, 5, 53-62	2.1	29
43	TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea. *Molecular Cancer Therapeutics*, **2016**, 15, 2767-2779	6.1	27
42	Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. *Supportive Care in Cancer*, **2019**, 27, 4011-4022	3.9	26
41	The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy-induced gastrointestinal toxicity. *International Journal of Cancer*, **2019**, 144, 2365-2376	7.5	25
40	Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. *Therapeutic Drug Monitoring*, **2013**, 35, 617-23	3.2	24
39	Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone. *International Journal of Clinical Pharmacology and Therapeutics*, **2007**, 45, 410-7	2	23
38	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. *Drug Metabolism and Disposition*, **2007**, 35, 128-38	4	20
37	Chemotherapy-induced gut toxicity and pain: involvement of TLRs. *Supportive Care in Cancer*, **2016**, 24, 2251-2258	3.9	19
36	Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. *British Journal of Clinical Pharmacology*, **2012**, 73, 786-94	3.8	19
35	Alcohol-induced sedation and synergistic interactions between alcohol and morphine: a key mechanistic role for Toll-like receptors and MyD88-dependent signaling. *Brain, Behavior, and Immunity*, **2015**, 45, 245-52	16.6	18
34	Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. *British Journal of Clinical Pharmacology*, **2012**, 74, 835-41	3.8	18
33	Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. *Pain*, **2016**, 157, 2458-2466	8	17
32	TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells. *Breast Cancer Research and Treatment*, **2008**, 107, 15-24	4.4	17
31	Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies. *Clinical and Experimental Pharmacology and Physiology*, **2003**, 30, 845-8	3	17
30	Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. *British Journal of Clinical Pharmacology*, **2004**, 57, 105-11	3.8	17
29	Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2014**, 945-946, 171-7	3.2	16
28	Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2006**, 832, 114-20	3.2	16

27	CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation. *Basic and Clinical Pharmacology and Toxicology*, **2018**, 123, 320-326	3.1	15
26	Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis. *Pharmacogenomics and Personalized Medicine*, **2009**, 2, 9-19	2.1	15
25	Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study. *Supportive Care in Cancer*, **2015**, 23, 1233-6	3.9	14
24	Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome. *Integrative Cancer Therapies*, **2020**, 19, 1534735420928493	3	14
23	Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies--a method suitable for small (. *Therapeutic Drug Monitoring*, **2011**, 33, 688-93	3.2	13
22	Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2006**, 843, 302-9	3.2	11
21	The impact of liver transplant recipient and donor genetic variability on tacrolimus exposure and transplant outcome. *British Journal of Clinical Pharmacology*, **2019**, 85, 2170-2175	3.8	9
20	The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. *British Journal of Clinical Pharmacology*, **2006**, 61, 321-5	3.8	9
19	Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. *British Journal of Clinical Pharmacology*, **2018**, 84, 2433-2442	3.8	7
18	Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. *Cancer Chemotherapy and Pharmacology*, **2017**, 79, 431-434	3.5	7
17	Response to No Influence of ABCB1 Haplotypes on Methadone Dosage Requirement *Clinical Pharmacology and Therapeutics*, **2008**, 83, 669-670	6.1	6
16	Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. *British Journal of Clinical Pharmacology*, **2004**, 57, 456-63	3.8	6
15	Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. *British Journal of Clinical Pharmacology*, **2008**, 65, 347-54	3.8	5
14	Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. *Pharmacogenetics and Genomics*, **2019**, 29, 9-17	1.9	5
13	Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation. *Indian Journal of Gastroenterology*, **2021**, 40, 5-21	1.9	5
12	Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation. *British Journal of Clinical Pharmacology*, **2019**, 85, 1015-1020	3.8	4
11	Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?. *Therapeutic Drug Monitoring*, **2019**, 41, 528-532	3.2	4
10	Site-specific contribution of Toll-like receptor 4 to intestinal homeostasis and inflammatory disease. *Journal of Cellular Physiology*, **2021**, 236, 877-888	7	4

List of Publications

9	Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. *British Journal of Clinical Pharmacology*, **2021**, 87, 3901-3909	3.8	3
8	Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy. *Cancer Chemotherapy and Pharmacology*, **2019**, 83, 217-236	3.5	3
7	Drugs against Acute and Chronic Pain **2012**, 403-428		2
6	No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation. *Frontiers in Pharmacology*, **2019**, 10, 1686	5.6	1
5	Intestinal accumulation of silica particles in a rat model of dextran sulfate sodium-induced colitis. *Annals of Gastroenterology*, **2019**, 32, 584-592	2.2	1
4	Brain-Immune Interactions as the Basis of Gulf War Illness: Clinical Assessment and Deployment Profile of 1990-1991 Gulf War Veterans in the Gulf War Illness Consortium (GWIC) Multisite Case-Control Study. *Brain Sciences*, **2021**, 11,	3.4	1
3	Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability.. *Inflammatory Intestinal Diseases*, **2021**, 6, 199-209	2.5	1
2	Clinically Significant Interactions with Anti-addiction Agents **2016**, 565-577		
1	A PRIMER EXTENSION DENATURING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR THE IDENTIFICATION OF THREE ABCC2 GENETIC POLYMORPHISMS. *Journal of Liquid Chromatography and Related Technologies*, **2014**, 37, 1249-1256	1.3	